Overview of the global non-invasive prenatal testing market

The invasive methods of prenatal testing can cause miscarriages and are painful. This resulted in the development of non-invasive prenatal testing (NIPT) through advancements in genomic sciences and bioinformatic analytical tools. NIPT was introduced in the year 2011. This enabled physicians to carry out a safe screening and detection of chromosomal abnormalities in fetuses. Research analysis on the global non-invasive prenatal testing market identifies that the growing preference for non-invasive methods over invasive methods will be one of the major factors that will have a positive impact on the growth of the market. NIPT reduces the number of false-positive results. NIPT will continue to gain popularity because it does not require trained healthcare professionals to conduct the test. Technavio’s market research analysts predict that this market will grow at a CAGR of close to 17% by 2021.

The awareness about NIPT is increasing among people due to the rising penetration of the Internet in the Americas. This results in an increased effort on preventing anomalies in infants. According to the studies, the rate of advanced maternal age (AMA) in the US is more than 9% for first-time mothers. The increasing maternal age drives the risk of chromosomal abnormalities. This encourages the health-conscious mothers in the region to adopt NIPT. Furthermore, the growing awareness and increasing number of genetic tests performed in the countries such as the US, Brazil, Canada, and Mexico will boost the demand for NIPT.

Competitive landscape and key vendors

The non-invasive prenatal testing market is consolidated and characterized by the presence of key vendors. These market players are focusing on making NIPT a diagnostic procedure through innovations. A large number of vendors of the non-invasive prenatal testing (NIPT) market in countries such as the US and China have established their presence in the market.

Key vendors in this market are -

• BGI Genomics
• Illumina
• Laboratory Corporation of America Holdings
• Quest Diagnostics

Other prominent vendors in the market include Agilent Technologies, Berry Genomics, F. Hoffman-La Roche, LifeCodexx, Natera, and PerkinElmer.

Segmentation by application and analysis of the non-invasive prenatal testing market

• Trisomy
• Microdeletions

Trisomy is a numerical abnormality, which is caused in the autosomes of chromosomes. Trisomy procedure is a painless procedure, which enables the detection of trisomies as early as seven weeks in comparison to invasive methods of testing. The trisomy segment is witnessing growth due to the shift of NIPT as a diagnostic procedure for trisomy testing. Furthermore, the increase in innovations will propel growth in this segment for the next four years.

Segmentation by end-user and analysis of the non-invasive prenatal testing market

• Diagnostic centers
• Hospitals

The hospital infrastructure and genomic sequencing professionals in multi-chain hospitals perform NIPT. Hospitals are also conducting NIPT as a routine diagnostic test for all pregnant women. The adoption of non-invasive methods such as ultrasonography and serum screening is increasing in this healthcare sector due to the ease of handling and the quick generation of test results.

Key questions answered in the report include

• What will the non-invasive prenatal testing marketsize and the growth rate be in 2021?
• What are the key factors driving the global non-invasive prenatal testing market?
• What are the key non-invasive prenatal testing market trends impacting the growth?
• What are the challenges to market growth?
• Who are the key vendors in the global non-invasive prenatal testing market?
• What are the market opportunities and threats faced by the vendors in the global non-invasive prenatal testing market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global non-invasive prenatal testing market?